FASLODEX Offers Another Way to Regain Control

For postmenopausal patients with hormone-responsive breast cancer experiencing first recurrence or progression following antiestrogen failure, studies in comparisons with ARIMIDEX® (anastrozole) Tablets confirm...

FASLODEX:

Proven effective based on objective response* rate and time-to-progression data1

View clinical data

FASLODEX:

Proven effective, with median overall survival of 2+ years and median time to disease progression of 5+months1,2

View the data
†Aromatase inhibitor
*Objective response = complete
response (CR) + partial
response (PR).
  1. Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer. 2003;98(2):229-238.
  2. Howell A, Pippen J, Elledge RM, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer. 2005;104(2):236-239.
  3. Wakeling AE. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer. 2000;7(1):17-28.
  4. Data on file, DA-FAS-08. Wilmington, DE: AstraZeneca Pharmaceuticals LP.
  5. Mauriac L, Pippen JE, Albano JQ, Gertler SZ, Osborne CK. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer. 2003;39(9):1228-1233.
  6. Data on file, DA-FAS-09. Wilmington, DE: AstraZeneca Pharmaceuticals LP.
  7. Faslodex [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2004.
  8. Pippen J. Similar time to response between fulvestrant and anastrozole: comparison from two phase III trials. Abstract presented at San Antonio Breast Cancer Symposium, December 10, 2005, San Antonio, TX. Abstract 5092.
  9. Dodwell D, Pippen J. Time to response: comparison of fulvestrant and oral endocrine agents. Clin Breast Cancer. 2006;7(3):244-247.
  10. Data on file, DA-FAS-10. Wilmington, DE: AstraZeneca Pharmaceuticals LP.
  11. Data on file, DA-FAS-12. Wilmington, DE: AstraZeneca Pharmaceuticals LP.
  12. FASP6125: Administration of ‘Faslodex’—a monthly intramuscular (i.m.) injection. Macclesfield, Cheshire, UK: AstraZeneca Pharmaceuticals LP; January 2005.
  13. Robertson JF, Nicholson RI, Bundred NJ, Burton G, Osborne CK, Mauriac L; Comparison of the short-term biological effects of 7α-[9-(4,4,5,5,5-pentafluoropentylsylfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17β-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res. 2001;61(18):6739-6746.
  14. Vergote I, Robertson JF, Kleeberg U, et al; for the Trial 0020 and 0021 Investigators. Postmenopausal women who progress on fulvestrant (‘Faslodex’) remain sensitive to further endocrine therapy. Breast Cancer Res Treat. 2003;79(2):207-211.